Gerresheimer (ETR:GXI) has been upgraded to Buy in a report by DZ BANK today.
- Updated: September 16, 2016
Yesterday Gerresheimer (ETR:GXI) traded 0.00% even at 72.55EUR. The company’s 50-day moving average is 0.00EUR and its two hundred day moving average is 0.00EUR. The last stock price is up 0.00% relative to the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time period. Trading volume was held steady, with 0 shares of GXI changing hands on par with the typical 0 shares..
DZ BANK has upgraded Gerresheimer(ETR:GXI) to Buy in a statement released 9/13/2016.
On 9/12/2016, Joh. Berenberg Gossler & Co. KG reported about Gerresheimer(ETR:GXI) upped the target price from 0.00EUR to 80.00EUR that suggested an upside of 0.10%.
See Chart Below:
With a market cap of 0.0 EUR, Gerresheimer has a price-earnings of 0 with a one-year low of 0.00EUR and a 52 week high of 0.00EUR.
General Company Details For Gerresheimer (ETR:GXI)
Gerresheimer AG is a Germany-based holding company and manufacturer of specialty products made of glass and plastic for the pharmaceutical and healthcare industries. The Company operates four business segments: Tubular Glass; Molded Glass; Plastic Systems, and Life Science Research. The Tubular Glass segment produces glass tubes converted to primary packaging. The Molded Glass segment produces glass primary packaging for pharmaceuticals, cosmetics products and specialty beverages and foods. The Plastic Systems segment produces customer-specific plastic systems fir pharmaceutics, diagnostics and medical technologies, and plastic containers mainly as primary packaging for pharmaceuticals and healthcare. The Life Science Research segment is focused primarily on specific tubular glass products and paste mould products for research and development in the pharmaceutical and life sciences industry and for general laboratory use and offers beakers, bottles and flasks, and among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.